ArticleScientific reports2025
Comparison of Simoa, high‑sensitivity ELISA, and CLIA for serum neurofilament light chain quantification in multiple sclerosis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- HAND in Africa: prevalence, diagnostic challenges and the search for objective markers.Journal of neurovirology · 2026Review
- Neurofilament Light Chain (NfL) in Neurodegenerative Diseases: Biological and Clinical Significance, Multi-Omics Integration, and AI-Driven Biomarker Modeling for Precision Therapy.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Challenges and Innovation for Diagnosing and Treatment of Secondary Progressive Multiple Sclerosis.International journal of molecular sciences · 2026Review
- Seric Molecular Markers Correlated with Stroke Rehabilitation Outcomes: A Narrative Review.Life (Basel, Switzerland) · 2026Review
- Translating blood-based biomarkers into Alzheimer's disease clinical practice: screening, diagnosis, and longitudinal monitoring.Frontiers in aging neuroscience · 2026Review
- Serum neurofilament light chain in multiple sclerosis: from biological signal to clinically informed decision-making.Frontiers in neurologyReview
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
Abstract
Serum neurofilament light chain (sNfL) reflects neuro‑axonal injury, and is an emerging biomarker in multiple sclerosis (MS). This prospective cross-sectional study compared analytical agreement and clinical applicability among three analytical platforms. Serum samples from adult MS patients were analysed by single molecule array (Simoa) (frozen samples), high-sensitivity ELISA (hsELISA) (frozen samples), and fully automated chemiluminescent immunoassay (CLIA) (fresh and frozen samples). Simoa and hsELISA were strongly correlated (rₛ = 0.796) without systematic bias. CLIA with frozen samples showed higher sNfL levels (relative bias: 39.53% vs. Simoa; 29.56% vs. hsELISA). CLIA with fresh samples correlated very strongly with Simoa (rₛ = 0.820) and strongly with hsELISA (r
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.